160 related articles for article (PubMed ID: 8647853)
41. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
42. Analysis of HLA-B*44 alleles encoded on extended HLA haplotypes by direct automated sequencing.
Petersdorf EW; Setoda T; Smith AG; Hansen JA
Tissue Antigens; 1994 Oct; 44(4):211-6. PubMed ID: 7871521
[TBL] [Abstract][Full Text] [Related]
43. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
[TBL] [Abstract][Full Text] [Related]
44. Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex.
Macdonald W; Williams DS; Clements CS; Gorman JJ; Kjer-Nielsen L; Brooks AG; McCluskey J; Rossjohn J; Purcell AW
FEBS Lett; 2002 Sep; 527(1-3):27-32. PubMed ID: 12220628
[TBL] [Abstract][Full Text] [Related]
45. The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.
Ma W; Stroobant V; Heirman C; Sun Z; Thielemans K; Mulder A; van der Bruggen P; Van den Eynde BJ
J Immunol; 2019 Jan; 202(2):451-459. PubMed ID: 30559321
[TBL] [Abstract][Full Text] [Related]
46. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
[TBL] [Abstract][Full Text] [Related]
47. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
Kessler JH; Mommaas B; Mutis T; Huijbers I; Vissers D; Benckhuijsen WE; Schreuder GM; Offringa R; Goulmy E; Melief CJ; van der Burg SH; Drijfhout JW
Hum Immunol; 2003 Feb; 64(2):245-55. PubMed ID: 12559627
[TBL] [Abstract][Full Text] [Related]
48. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain.
Fleischhauer K; Avila D; Vilbois F; Traversari C; Bordignon C; Wallny HJ
Tissue Antigens; 1994 Nov; 44(5):311-7. PubMed ID: 7878657
[TBL] [Abstract][Full Text] [Related]
49. Expression of classic and nonclassic HLA class I antigens in uveal melanoma.
Anastassiou G; Rebmann V; Wagner S; Bornfeld N; Grosse-Wilde H
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2016-9. PubMed ID: 12714638
[TBL] [Abstract][Full Text] [Related]
50. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
51. T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.
Chen Q; Smith M; Nguyen T; Maher DW; Hersey P
Cancer Immunol Immunother; 1994 Jun; 38(6):385-93. PubMed ID: 8205560
[TBL] [Abstract][Full Text] [Related]
52. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
53. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
Brichard VG; Herman J; Van Pel A; Wildmann C; Gaugler B; Wölfel T; Boon T; Lethé B
Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071
[TBL] [Abstract][Full Text] [Related]
54. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
55. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1.
Lake DF; Salgaller ML; van der Bruggen P; Bernstein RM; Marchalonis JJ
Int Immunol; 1999 May; 11(5):745-51. PubMed ID: 10330280
[TBL] [Abstract][Full Text] [Related]
56. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
Zakut R; Topalian SL; Kawakami Y; Mancini M; Eliyahu S; Rosenberg SA
Cancer Res; 1993 Jan; 53(1):5-8. PubMed ID: 8416750
[TBL] [Abstract][Full Text] [Related]
57. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
58. A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells.
Ayyoub M; Mazarguil H; Monsarrat B; Van den Eynde B; Gairin JE
J Biol Chem; 1999 Apr; 274(15):10227-34. PubMed ID: 10187808
[TBL] [Abstract][Full Text] [Related]
59. Binding of radioiodinated influenza virus peptides to class I MHC molecules and to other cellular proteins as analyzed by gel filtration and photoaffinity labeling.
Reyes VE; Lu S; Humphreys RE
Mol Immunol; 1991; 28(4-5):341-8. PubMed ID: 2062316
[TBL] [Abstract][Full Text] [Related]
60. The relationship between HLA-A, B, DQ, and DR antigens and asbestos-induced lung disease.
Shih JF; Hunninghake GW; Goeken NE; Galvin JR; Merchant JA; Schwartz DA
Chest; 1993 Jul; 104(1):26-31. PubMed ID: 8325081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
